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ABSTRACT
Background. Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a multisystem autoimmune
disorder associated with significant morbidity and mortality. Approximately 80–90% of patients have circulating ANCAs.
Long-term outcomes appear to be improving. This retrospective study analyses the incidence and patient outcomes over a
period of 23 years at a single tertiary centre.
Methods. Outcomes of patients diagnosed with AAV between 1 January 1988 and 31 December 2010 were collected
retrospectively. Data including patient demographics, age of diagnosis, dates of starting renal replacement therapy, death
and biochemistry results were collected. Patients were divided into two cohorts (1988–99 and 2000–10) and analysed using
Stata software (StataCorp, College Station, TX, USA).
Results. A complete dataset was obtained for 273 patients. Of these patients, 101 were diagnosed between 1988 and 1999
while 172 were diagnosed between 2000 and 2010. The number of patients diagnosed with AAV increased from 2.2/million
in 1988 to 10.3/million in 2010. A higher proportion of patients (56.4%) in the earlier cohort presented with creatinine
>500lmol/L compared with the later cohort (30.2%; P<0.001). Overall patient survival improved significantly between the
two cohorts. Cohort 1 had a median survival of 59 months compared with 125 months for Cohort 2 (P¼0.003).
Conclusions. This study shows that AAV is being diagnosed at an earlier stage, resulting in improved outcomes. This may
be because of improvements in the management of AAV and chronic kidney disease.
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INTRODUCTION
Anti-neutrophil cytoplasmic autoantibody (ANCA)–associated
vasculitis (AAV) is a multisystem disease associated with signif-
icant morbidity and mortality. Approximately 80–90% of
patients demonstrate the presence of circulating ANCAs. Three
major phenotypes are described: granulomatosis with polyan-
giitis (GPA), eosinophilic GPA and microscopic polyangiitis.
Although AAV is usually considered a single entity, there re-
main significant differences in genetics, epidemiology, clinical
presentations and outcomes in the major three phenotypes.
Untreated systemic AAV has a mortality rate of 90% within the
first 2 years [2]. Treatment with immunosuppression has made
significant improvements in survival outcomes, with the 5-year
survival rate reaching 75% [3]. Several factors are associated
with outcomes in AAV: early diagnosis, organ involvement, pre-
senting renal function, immunosuppression, ANCA serotype,
clinical phenotype, renal histology and the number of relapses
[4–8]. Recent advances in the understanding of the pathogene-
sis, increased awareness and advancements in treatment proto-
cols may be associated with increased patient survival.
An increased tendency to optimize immunosuppression
with reduced use of cyclophosphamide and prednisolone could
be responsible for improvements in infection-related vasculitis
outcomes. Furthermore, chronic kidney disease (CKD) manage-
ment has changed with the widespread use of renin–angioten-
sin–aldosterone system blockers and statins and rigid blood
pressure targets should reduce cardiovascular outcomes.
Published data from Germany and Holland have confirmed this
[9, 10].
In this study we analysed outcomes of 273 AAV patients di-
agnosed and treated in a single tertiary centre over a period of
23 years.
MATERIALS ANDMETHODS
A retrospective study was performed to analyse outcomes of all
the patients diagnosed with AAV at a single centre between 1
January 1988 and 31 December 2010. Follow-up continued up to
1 January 2014. Our centre is a regional tertiary renal service
provider for the population of Lancashire and South Cumbria.
This includes East Lancashire Hospitals (Blackburn Hospital),
West Lancashire Hospitals (Blackpool Victoria Infirmary) and
North Lancashire Hospitals including Lancaster Royal
Infirmary, Westmorland General Hospital and Furness General
Hospital. Patients from North Cumbria are not part of our catch-
ment area and were not included. Multiple databases were
screened for complete information. Data were collected using
the electronic records of kidney biopsies performed in patients
diagnosed with AAV. All the biopsies confirming pauci-immune
necrotizing glomerulonephritis with or without crescent forma-
tion were considered as evidence of small-vessel vasculitis. The
Histopathology Department uses immunohistochemistry for di-
agnosing immune complex deposits. If non-specific immune
complex staining was reported, then a lack of immune dense
deposits on electron microscopy was essential for inclusion of
the patient. All the biopsy reports were reviewed by two asses-
sors (S.W. and A.D.). Electronic patient records were assessed to
confirm if patients met the inclusion and exclusion criteria. The
department also maintains an accurate cyclophosphamide
database. This was reviewed along with the biopsy database to
find all eligible patients. Patients were excluded if they
were <16 years of age, had positive anti–glomerular basement
membrane (anti–GBM) antibodies, were only treated with
azathioprine and/or prednisolone or they were deemed unfit
for renal biopsy and/or cyclophosphamide-based
immunosuppression.
Electronic patient records were analysed in order to collect
data regarding ANCA serology, patient demographics, renal sur-
vival and patient survival. ANCA testing took place by indirect
immunofluorescence (IIF). IIF was introduced in the centre
during the early 1990s, although the exact year is not known.
Enzyme-linked immunosorbent assay (ELISA) for proteinase 3
(PR3) and myeloperoxidase (MPO) was introduced later. Our lab-
oratory is a recognized regional centre for immunology work
and currently used the Phadia assay for ANCA.
All patients were treated with intravenous pulse cyclophos-
phamide and tapering doses of glucocorticoids. Plasma ex-
change was used for severe presentations of AAV, defined as
presenting creatinine 500 lmol/L and/or pulmonary haemor-
rhage. Our centre started using plasma exchange treatment for
AAV around 2000. It became standard practice in 2003 for
patients meeting the criteria set out by the European Vasculitis
Study Group (EUVAS) trials. Maintenance of immunosuppres-
sion was a combination of azathioprine or mycophenolate
mofetil with low-dose glucocorticoids. Data regarding immuno-
suppression treatments in two cohorts were not available and
therefore comparisons of treatment could not be made. The
CYCLOPS trial (Randomised Trial of Daily Oral versus Pulse
Cyclophosphamide as Therapy for ANCA-associated Systemic
Vasculitis) was published in 2009 and this protocol has been
used since 2009 [11]. Prior to 2009, patients were treated with
monthly pulses of intravenous cyclophosphamide for at least 6
months. Plasma exchange indications remained the same dur-
ing the study period; however, exact details of patients receiv-
ing this treatment in each cohort were not available. Patients
who had inadequate data were excluded (n¼ 41). The remaining
273 patients were followed up until the last appointment (1
January 2014) or death.
To compare the outcomes, patients were divided into two
cohorts according to the year of diagnosis:
• Cohort 1: diagnosed between 1 January 1988 and 31
December 1999 (12 years)
• Cohort 2: diagnosed between 1 January 2000 and 31
December 2010 (11 years).
The chi-squared test or Fisher’s exact test compared categor-
ical patient characteristics between the two cohort groups.
Kaplan–Meier curves and the log-rank test were used in an
unadjusted univariate analysis to determine which variables
should be included in a Cox regression model for predicting pa-
tient and renal survival, respectively. Variables were retained
for Cox regression modelling if the P-value was 0.1. Cox regres-
sion modelling compared patient and renal survival times be-
tween the two cohorts after adjusting for other factors that
were found to be significantly associated with patient and renal
survival, respectively, in the univariate analyses. The propor-
tionality assumption, which is needed for Cox regression, was
assessed, including time covariates in the model and looking at
the Schoenfeld residuals.
Statistical analyses were performed using Stata software
(StataCorp, College Station, TX, USA) [1].
Ethical approval
This study protocol was reviewed by the Hospital Research and
Development directorate and was approved as a service evalua-
tion project without a need for formal ethics approval.
2 | S. Whatmough et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/ckj/advance-article-abstract/doi/10.1093/ckj/sfy084/5094970 by U
niversity of C
entral Lancashire user on 25 Septem
ber 2018
RESULTS
Diagnosis of small-vessel vasculitis
In the area of Lancashire and South Cumbria, the incidence of
biopsy-proven renal involvement of AAV increased from 2.2/
million in 1988 to 10.3/million in year 2010 (Figure 1). In this
study, a total of 314 patients with AAV were identified.
Of the 314 patients, 41 had insufficient data and were ex-
cluded from the analysis. Of the remaining 273 patients, 101
were diagnosed between 1988 and 1999 (Cohort 1) and 172
patients were diagnosed between 2000 and 2010 (Cohort 2).
The median age of patients was 62 years: Cohort 1 had a median
age of 61 years and Cohort 2 had a median age of 63 years. The
median regional annual incidence of biopsy-proven renal in-
volvement of AAV was found to be 9.2/million population. This
was highest between 75 and 79 years of age (Figure 2). The aver-
age age at diagnosis was 59 years [standard deviation (SD) 15.8].
The main characteristics of the cohorts are shown in Table 1.
The median follow-up of all patients was 57 months [inter-
quartile range (IQR) 77.3] and that of still alive patients was
81 months (IQR 79.8).
There was a significantly higher proportion of patients with
a creatinine concentration >500 lmol/L at the time of diagnosis
(P< 0.001) in Cohort 1 compared with Cohort 2. For Cohort 1, the
median creatinine at diagnosis was 705 lmol/L (IQR 585) and for
Cohort 2 was 333 lmol/L (IQR 369.3). These remained true when
only patients with known ANCA status were included. For those
with known ANCA status, the median creatinine results for
Cohorts 1 and 2 were 614 lmol/L (IQR 739.8) and 330 (362.5), re-
spectively (P  0.001). There was a significantly lower proportion
of patients 75 years of age in Cohort 1 compared with Cohort 2
(P¼ 0.02). This result was not significant when only patients
with known ANCA status were included (P¼ 0.10). In Cohort 1,
the ANCA status was unknown in 42 of the 101 patients.
ANCAs were discovered in 1981 and the significance of their
association was established 4 years later. Even after the associa-
tion of ANCA and small-vessel vasculitis was established in
1985, it took many years for standardization of the assay and ac-
ceptance of it as a clinical tool. Furthermore, antigen-specific
ELISA was discovered later. Overall, ANCAs were not used
routinely until the early 1990s in most centres, including ours.
This explains the high percentage of unknown ANCA status for
patients in Cohort 1. ANCA measured by IIF and ELISA at the
time of diagnosis or noted to be positive during any stage of fol-
low-up were included for assessment. In Cohort 2, only three
patients had an unknown ANCA status.
Patient survival using all patients
Overall, 1-, 5- and 10-year patient survival was 78.8, 49.5 and
19.1%, respectively. Overall, the median survival for all patients
was 60 months. The Kaplan–Meier patient survival curves for
the two cohorts (n¼ 273) are shown in Figure 3. Cohort 1 had a
median patient survival of 59 months compared with
125 months for Cohort 2 (P¼ 0.003).
Unadjusted univariate analysis, using the log-rank test,
found that patients diagnosed at 75 years of age (P¼ 0.013) and
with creatinine 500 lmol/L (P¼ 0.035) were significantly asso-
ciated with worse survival rates. Gender approached statistical
significance (P¼ 0.08).
In the adjusted analysis, Cohort 1 and patients >75 years of
age had a worse prognosis when compared with their counter-
parts (P¼ 0.001 and P¼ 0.002, respectively). The estimated haz-
ard ratio for Cohort 2 was 0.55 when compared with Cohort 1.
The estimated hazard ratio for patients 75 years of age was
2.03 (Table 2).
Renal survival using all patients
Overall, renal survival for 12 months was 54.2%. This dropped to
33.7% at 5 years and was 12.5% at 10 years. The median death-
censored renal survival was only 25 months and death-uncen-
sored renal survival was 65 months. The Kaplan–Meier renal
survival curves for the two cohorts (n¼ 273) are shown in
Figure 4. Cohort 1 had a median renal survival of 9 months com-
pared with 43 months for Cohort 2 (P¼ 0.003). Of the patients
who required initial renal replacement therapy, 17% experi-
enced renal recovery.
Unadjusted univariate analyses, using the log-rank test, for
male gender (P¼ 0.033) and diagnosis creatinine 500 lmol/L
FIGURE 1: Patients diagnosed with AAV per million population by the year of diagnosis.
Comparing outcomes of biopsy-proven ANCA glomerulonephritis | 3
D
ow
nloaded from
 https://academ
ic.oup.com
/ckj/advance-article-abstract/doi/10.1093/ckj/sfy084/5094970 by U
niversity of C
entral Lancashire user on 25 Septem
ber 2018
(P< 0.001) were significantly associated with worse renal sur-
vival for all patients and therefore were retained in the Cox re-
gression in addition to age at diagnosis and cohort to provide an
adjusted analysis (Table 3).
In the adjusted analysis, diagnosis creatinine 500lmol/L
(P< 0.001) was significantly associated with poorer renal survival.
Gender (P¼ 0.08) was approaching statistical significance and age
at diagnosis (p¼ 0.11) was not found to be significant. The esti-
mated hazard ratio for Cohort 2 was 0.75, for males it was 1.32 and
for patients with diagnosis creatinine500lmol/L it was 1.77.
DISCUSSION
Two large European studies have shown that outcomes of AAV
are improving [9, 10]. Although 5-year outcome data from
England have been published before, long-term outcome data
remain limited [6]. Our study, while confirming these findings,
has also demonstrated some new insights into long-term out-
comes of AAV.
Increasing diagnosis of AAV
At our centre, annual diagnosis of AAV appears to be steadily
increasing over a period of two decades, from 2.2/million in
1988 to 10.3/million in 2010. A significant increase in the diagno-
sis was noted after introduction of ANCA assays, with this
reflecting improved diagnosis of AAV [8, 12, 13]. Our data are
from 1988 and ANCAs were discovered in 1985. ANCA assays
were introduced in the 1990s in our centre and widespread use
was not until the late 1990s. Therefore it is possible that during
FIGURE 2: Patients diagnosed with AAV between 1988 and 2010 across different age groups.
Table 1. Patient characteristics for Cohort 1 (1988–99) and Cohort 2 (2000–10)
Variable 1988–99 (n¼ 101) 2000–10 (n¼ 172) P-value
Gender, n (%)
Male 62 (61.4) 96 (55.8) 0.38
Age, n (%)
75 years 9 (8.9) 34 (19.8) 0.02
Creatinine, n (%)
500 lmol/L 57 (56.4) 52 (30.2) <0.001
Creatinine at diagnosis (lmol/L), median (IQR) 705 (585) 333 (369.3) <0.001
Patients with known ANCA status (n¼ 228) 1988–99 (n¼ 59) 2000–10 (n¼ 169) P-value
Gender, n (%)
Male 36 (61.0) 94 (55.6) 0.54
Age, n (%)
75 years 5 (8.5) 31 (18.3) 0.10
Creatinine, 500 mmol/L, n (%) 31 (52.5) 50 (29.6) 0.002
ANCA status, n (%)
PR3-ANCA 27 (45.8) 61 (36.1)
Negative 15 (25.4) 51 (30.2)
MPO-ANCA 17 (28.8) 57 (33.7) 0.45
Creatinine at diagnosis (lmol/L), median (IQR) 614 (739.8) 330 (362.5) <0.001
MPO, myeloperoxidase; PR3, proteinase 3.
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the early years of our study, underdiagnosis of AAV occurred
until the widespread use of ANCA assays became common
practice. This also explains the very high number of patients
with negative ANCA serology in the first cohort and the peak in-
cidence in 1995. For the later cohort, our centre has been using
the Phadia assay. Rather than a true increase in AAV incidence,
we suspect that the increasing number of patients with AAV is
due to these advancements in ANCA testing. These are highly
sensitive and accepted assays, and although the percentage of
seronegative patients decreased, it still remains higher than the
published literature. Reasons behind this are unclear. Published
European data suggest much greater rates of AAV diagnosis
(15–20/million population [14]. In our cohort, the number of
patients diagnosed with AAV was significantly lower than
expected. It is possible that a very small number of patients
were hospitalized at nearby centres in earlier years and there-
fore were missed in the incidence calculation. As incidence was
significantly low, even missing a few patients could influence
the results. Furthermore, we used biopsy as a criterion for diag-
nosis of AAV and 20% of patients do not have renal involve-
ment with AAV and every patient with renal involvement may
not undergo kidney biopsy. Our rate of diagnosis is higher than
published UK data using similar criteria [15]. However, a re-
cently published large histology study from the Southeast USA
over the same period of time shows a similar rate of diagnosis
of 7.9/million population using biopsy criteria [16].
A significantly higher proportion of patients >75 years of age
were diagnosed with AAV in the later cohort (P¼ 0.02; Table 2).
An increased acceptance of older patients undergoing invasive
investigations and potentially harmful treatments may account
for this. On the other hand, an increased number of patients
>75 years of age being diagnosed with AAV may also explain
the increased diagnosis in the later cohort. However, the in-
creasing age in the second cohort may simply reflect the in-
creasing age of the general population over this time period.
Nonetheless, it is impossible to know if the true incidence of
AAV is increasing and further epidemiological studies in the
current era would be helpful to resolve this conundrum.
Our study also suggests improved diagnosis in the second co-
hort, similar to data found by Hilhorst et al. [10]. In their cohort, the
average time to diagnosis had decreased over time. Although we
do not have data to confirm these findings, in the later cohort, a
significantly lower number of patients presented with serum cre-
atinine 500lmol/L. We postulate that this observation suggests
earlier diagnosis in the later cohort of patients.
AAV survival
Overall, patient survival was better for Cohort 2. Data regarding
treatment were not available, but this was expected to be a ma-
jor factor influencing the survival difference in the two cohorts.
However, this may not be limited to differences in treatment
protocol alone. Survival benefit appears to be greatest during
the early follow-up period; however, this benefit continues even
during the later period. Meta-analysis of four EUVAS trials also
showed very high mortality within the first 12 months, due to
infections as well as active vasculitis. Clearly, improving man-
agement during this period remains crucial. Early improvement
in survival is likely to be multifactorial. The EUVAS has per-
formed several high-quality randomized controlled trials
FIGURE 3: Kaplan–Meier curves showing patient survival by cohort for all
patients (n¼273, P¼0.003). See Supplementary data, Appendix S1 for details of
the number of patients at each time point.
Table 2. Hazard ratios from Cox regressions of patient survival for all
patients (N¼273, deaths¼136)
Variable Hazard ratio (95% CI) P-value
Cohort
2000–10 0.55 (0.39–0.79) 0.001
Age at diagnosis
75 years 2.03 (1.30–3.19) 0.002
Gender
Male 1.31 (0.92–1.86) 0.13
FIGURE 4: Kaplan–Meier curves showing renal survival by cohort for all patients
(n¼273, P¼0.003). See Supplementary data, Appendix S2 for details of the num-
ber of patients at each time point.
Table 3. Hazard ratios from Cox regressions of renal survival for all
patients (N¼273, failures¼180)
Variable Hazard ratio (95% CI) P-value
Cohort
2000–10 0.75 (0.55–1.03) 0.07
Age at diagnosis
75 years 1.41 (0.93–2.13) 0.11
Gender
Male 1.32 (0.97–1.78) 0.08
Creatinine
500 lmol/L
1.77 (1.30–2.40) <0.001
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focusing on treatment of AAV. This evidence has been pivotal
in forming vasculitis treatment guidelines. These guidelines
have assisted the vasculitis community in rationalizing the
treatment of AAV and the possible reduction in early mortality
due to infections and active vasculitis.
Regarding improved survival during long-term follow-up,
again there are several reasons. With emerging evidence, it is
likely that there is an increased awareness of cancer surveil-
lance among the vasculitis community, which would reduce
late mortality [17–19]. In addition to improved cancer surveil-
lance, further reduction in late mortality in the later cohort
probably reflects improved management of CKD. There were
significantly more elderly patients in the second cohort. This
suggests that many older patients with vasculitis would have
not been included in the first cohort because they were not con-
sidered fit enough for an invasive procedure like kidney biopsy.
Recently Rhee et al. [20] published composite outcomes of
death and end-stage renal disease (ESRD) for 544 AAV patients
from the USA. They showed a significant reduction in the risk
of death and ESRD over a period of 25 years. Interestingly, al-
though they observed changes and variations in cyclophospha-
mide treatments over 25 years, this did not alter the outcome.
There are other smaller studies with variable inclusion criteria
and variable outcomes, e.g. Drooger et al. [21] and Caravaca et al.
[22]. Nonetheless, it is worth noting that not all long-term epide-
miology studies of AAV have shown improved outcomes.
Improved renal survival of patients with AAV, mainly GPA,
in recent years has been reported in other studies [9]. In our co-
hort, we found a trend towards improvement of renal survival
(P¼ 0.07). Serum creatinine 500 lmol/L at the time of diagnosis
was significantly associated with poorer renal outcome. This
finding has also been previously reported and would suggest a
degree of severity of renal involvement when diagnosed with
vasculitis [6, 23, 24]. Without immunosuppression, these
patients would experience significant CKD and hence poor
long-term outcomes. There was also a trend towards poor renal
survival among male patients. Although of interest, this finding
is less likely to have any impact on clinical practice. Overall,
male gender is a well-known risk factor for progression of
unspecified causes of CKD and some specific aetiologies such as
immunoglobulin A nephropathy [25, 26].
Despite the improved renal survival, we found poor renal re-
covery for patients requiring initial renal replacement therapy
at the time of diagnosis when compared with the published
data. Although histology was essential for the diagnosis of
small-vessel vasculitis, the Berden classification system was in-
troduced in 2010 and our cohort lacks these details. An attempt
was made to retrospectively classify the biopsies but was not
accurate due to the lack of uniform reporting methods [27]. In a
Dutch cohort, the number of patients requiring renal replace-
ment therapy was much smaller than our cohort. Higher serum
creatinine itself is associated with poor renal survival.
CONCLUSIONS
To our knowledge, this study presents the largest cohort of
British AAV patients followed over 2 decades. There has been
an increasing rate of diagnosis of AAV in Lancashire and South
Cumbria over the last 20 years, with most patients diagnosed at
65–69 years of age. The study reassuringly shows improved
overall and renal survival of AAV patients in recent decades.
Although it shares all the limiting factors of a retrospective
study conducted over a long period of time, it represents real
clinical practice outcomes. The EUVAS trials have given the
vasculitis community real insight into factors affecting survival;
however, these patients are treated with a strict trial protocol
designed by experts, are closely monitored and do not represent
true clinical practice outcomes. We hope that this study will
provide further insight to clinicians treating these complex vas-
culitis patients in their day-to-day practice.
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